| Date | Time | Source | Headline | Symbol | Company |
| 07/03/2024 | 1:00PM | iHub Newswire | FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent | | |
| 11/06/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023 | EU:IVA | Inventiva |
| 09/28/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva reports its 2023 first-half financial results and provides a corporate update | EU:IVA | Inventiva |
| 09/28/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva publie ses résultats financiers du 1er semestre 2023 et fait un point sur ses activités | EU:IVA | Inventiva |
| 09/28/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva reports its 2023 first-half financial results and provides a corporate update | EU:IVA | Inventiva |
| 09/20/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud | EU:IVA | Inventiva |
| 09/20/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea | EU:IVA | Inventiva |
| 09/20/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea | EU:IVA | Inventiva |
| 08/31/2023 | 1:30AM | GlobeNewswire Inc. | Inventiva annonce un financement d'environ 35,7 millions d'euros auprès d'investisseurs nouveaux et existants, constitué d'une augmentation de capital réservée de 30,6 millions d'euros et d'une émission de certificats de royalties de 5,1 mi | EU:IVA | Inventiva |
| 08/31/2023 | 1:30AM | GlobeNewswire Inc. | Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates | EU:IVA | Inventiva |
| 07/27/2023 | 4:33PM | GlobeNewswire Inc. | Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update | EU:IVA | Inventiva |
| 07/27/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva publie ses informations financières préliminaires du 1er semestre 2023¹ et fait un point sur ses activités | EU:IVA | Inventiva |
| 07/27/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update | EU:IVA | Inventiva |
| 07/27/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update | EU:IVA | Inventiva |
| 06/24/2023 | 2:00AM | GlobeNewswire Inc. | Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association | EU:IVA | Inventiva |
| 06/24/2023 | 2:00AM | GlobeNewswire Inc. | Inventiva annonce la présentation d’un abstract scientifique lors de la 82nd Scientific Sessions of the American Diabetes Association | EU:IVA | Inventiva |
| 06/24/2023 | 2:00AM | GlobeNewswire Inc. | Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association | EU:IVA | Inventiva |
| 06/13/2023 | 5:00PM | GlobeNewswire Inc. | Inventiva annonce les résultats positifs de l’étude clinique initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et NAFLD | EU:IVA | Inventiva |
| 06/13/2023 | 5:00PM | GlobeNewswire Inc. | Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD | EU:IVA | Inventiva |
| 06/08/2023 | 2:30AM | GlobeNewswire Inc. | Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients | EU:IVA | Inventiva |
| 06/08/2023 | 2:30AM | GlobeNewswire Inc. | Inventiva et Echosens lancent une initiative conjointe pour mieux sensibiliser l’opinion à la NASH et faciliter l’accès au dépistage pour les patients à risque | EU:IVA | Inventiva |
| 06/08/2023 | 2:30AM | GlobeNewswire Inc. | Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients | EU:IVA | Inventiva |
| 06/07/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva annonce cinq présentations scientifiques lors de l’EASL International Liver Congress™ 2023 | EU:IVA | Inventiva |
| 06/07/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023 | EU:IVA | Inventiva |
| 06/07/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023 | EU:IVA | Inventiva |
| 05/26/2023 | 4:00PM | GlobeNewswire Inc. | Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023 | EU:IVA | Inventiva |
| 05/26/2023 | 4:00PM | GlobeNewswire Inc. | Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunie le 25 mai 2023 | EU:IVA | Inventiva |
| 05/26/2023 | 4:00PM | GlobeNewswire Inc. | Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023 | EU:IVA | Inventiva |
| 05/25/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China | EU:IVA | Inventiva |
| 05/25/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva annonce que son partenaire Sino Biopharm a reçu l'approbation de sa demande d’IND par la NMPA pour démarrer le développement clinique de lanifibranor en Chine | EU:IVA | Inventiva |